Celiac Disease Foundation, in partnership with the University of Southern California (USC) Keck School of Medicine, and CDF Board member Dr. Michael S. Karp, Chief of the Division of Geriatric, Hospital, Palliative and General Internal Medicine, is proud to launch a pioneering celiac disease training program for Internal Medicine residents. This program is made possible […]
We fight to improve the lives of all affected by celiac disease and non-celiac gluten/wheat sensitivity NOW
ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]
In 1992, M.N. Marsh published a study aimed at measuring degrees of change seen in the structure of intestinal villi under microscopic scrutiny. Villi are finger-like projections which line the intestinal walls; their thin walls and large surface area are what allow for efficient absorption and digestion of nutrients. In patients with celiac disease, the […]
In addition to improving treatments and finding a cure for celiac disease, iCureCeliac® is helping researchers appreciate the realities of living with celiac disease, helping to influencing what they choose to research and why.
Patients with chronic diseases and their caregivers are demanding that any new health plan that emerges from Congress retains specific patient protections, including prohibiting pre-existing condition discrimination.
Celiac Disease Foundation (CDF) and the North American Society for the Study of Celiac Disease (NASSCD) are proud to announce Matthew Shale, MD, PhD as the recipient of the Young Investigator Award.